Mariana Oncology, a radiopharma startup founded by top-tier VCs, nabs $175M Series B
Despite advances in developing radiopharmaceuticals, manufacturing such drugs remains a challenge. One startup’s plan to tackle the issue is beginning to round into form and, simultaneously, it’s receiving a hearty, cash-rich endorsement.
Mariana Oncology, a biotech incubated by three prominent life sciences VC firms, closed a $175 million Series B round Thursday morning, as its first pipeline program prepares to begin human testing sometime next year. The startup, founded as Curie Therapeutics by Atlas Venture, RA Capital Management and Access Biotechnology, will focus that drug candidate in small cell lung cancer patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
